US trial go-ahead for Thoratec's CABG (coronary artery bypass graft) graft:
This article was originally published in Clinica
Executive Summary
Thoratec Laboratories has received permission from the US FDA to begin a clinical trial of its Aria coronary artery bypass graft (CABG) under an investigational device exemption. The AEGIS/US (AlternativE Graft Investigational Study) trial will assess the prosthetic graft, which incorporates the company's proprietary biomaterial Thoralon, in bypass patients who have too few or no suitable vessels of their own. Pleasanton, California-based Thoratec said it was the first company to gain FDA approval to begin US clinical trials for a prosthetic aorta-to-coronary artery bypass graft for such patients. Trials of the graft have been underway in Canada since late last year.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.